Yunnan Baiyao Group Co Ltd

Yunnan Baiyao released its 2026 interim report, with total operating revenue of 21.884 billion yuan, up 2.95% year-on-year, and net profit attributable to the parent company of 3.701 billion yuan, up 1.88% year-on-year. Net cash inflow from operating activities was 4.106 billion yuan, up 3.66% year-on-year. The company's asset-liability ratio was 25.56%, gross margin was 30.06%, return on equity was 9.03%, and diluted earnings per share was 2.07 yuan. The number of shareholders was 189,400, and the top ten shareholders held 67.39% of the total share capital.

Yunnan Baiyao released its 2026 interim report. First-half net profit attributable to the parent was 3.7 billion yuan, up 1.9% year on year. Operating revenue was 21.88 billion yuan, up 2.9% year on year. Net profit attributable to the parent after deducting non-recurring items was 3.52 billion yuan, up 1.7% year on year. Net operating cash flow was 4.106 billion yuan, up 3.7% year on year. Earnings per share were 2.0743 yuan. In the second quarter, operating revenue was 10.28 billion yuan, down 1.3% year on year, and net profit attributable to the parent was 1.66 billion yuan, down 2.0% year on year. As of the end of the second quarter, total assets were 55.145 billion yuan, up 1.6% from the end of the previous year, and net assets attributable to the parent were 40.973 billion yuan, up 2.3% from the end of the previous year. The company said that as health demand rises and the traditional Chinese medicine industry develops with higher quality, its business has maintained growth momentum, and core products such as Yunnan Baiyao aerosol and adhesive bandages hold the top position in their relevant markets.